IBM’s Watson is set to generate one billion dollars in revenue by 2018, a transcript leaked to the Wall Street Journal reveals. But CEO Virginia Rometty has much bigger ambitions for the Jeopardy!-winning supercomputer. The executive reportedly told her team she was looking to hit the $10 billion mark in that timeframe, a seemingly unreachable goal in view of the fact that, according to the document, the platform made the company less than $100 million as of late October. Still, Watson is poised to become the fastest IBM business to achieve $1 billion in sales, which is quite the achievement for a system originally designed to answer trivia questions. So Big Blue is staying optimistic.
“Watson has rapidly moved from an industry-first research initiative to a commercial reality” that tackles business and social problems, an IBM spokesman was quoted as saying. “IBM is making excellent progress with clients and with partners in advancing Watson, and we are excited about Watson’s future as a cloud service and as technology that will change lives.”
The technologies behind Watson constitute the foundation of IBM’s cognitive computing offering, which mashes real time and predictive analytics together with different datasets and sophisticated visualization techniques to make information more accessible to end users. The software is already starting to show promise in the healthcare industry, where it’s used to advance medical research and personalize treatment plans on an individual basis according to each patient’s unique requirements. At WellPoint, Watson is used to drive operational efficiencies by streamlining day-to-day activities. And the system helps the Memorial Sloan-Kettering Cancer Center in New York create treatment recommendations based on factors such as patient records, test results and genetic data – functionality that Wikibon editor Bert Latamore sees entering the mainstream this decade. The IBM Watson team is working to make that happen.
According to Rob High, development director of the platform, Big Blue is offering the ability to run natural language queries against massive datasets with unprecedented accuracy.
“We wanted to apply Watson where we could make a difference,” the executive explained, which is why the company is collaborating with Memorial Sloan-Kettering on leveraging the supercomputer to combat cancer.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Date: January 9, 2014